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ABSTRACT 
Germline aberrations in critical DNA repair and DNA-damage response (DDR) 
genes cause cancer predisposition, while various tumors harbor somatic 
mutations causing defective DDR/DNA repair. The concept of synthetic 
lethality can be exploited in such malignancies, as exemplified by approval of 
poly(ADP-ribose) polymerase inhibitors for treating BRCA1/2 mutated ovarian 
cancers. Herein, we detail how cellular DDR processes engage various 
proteins that sense DNA damage, initiate signaling pathways to promote cell 
cycle checkpoint activation, trigger apoptosis and coordinate DNA repair. We 
focus on novel therapeutic strategies targeting promising DDR targets and 
discuss challenges of patient selection and the development of rational drug 
combinations. 
 
SIGNIFICANCE: Various inhibitors of DDR components are in preclinical and 
clinical development. A thorough understanding of DDR pathway complexities 
must now be combined with strategies and lessons learnt from the successful 
registration of PARP inhibitors in order to fully exploit the potential of DDR 
inhibitors and to ensure their long-term clinical success. 
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INTRODUCTION  
Failure to accurately repair damaged DNA in cells manifests in various clinical 
phenotypes, including neurodegeneration, infertility, immunodeficiencies and 
cancer susceptibility (1,2). Furthermore, the production of DNA damage in 
cells following exposure to carcinogens increases cancer risk (3). Germline 
mutations in genes encoding key players in the DNA damage response (DDR), 
including BRCA1, BRCA2, BLM, FANCA, TP53, RAD51C and MSH2, result in 
cancer susceptibility syndromes (1), in part because failure to adequately 
protect the genome against endogenous and exogenous sources of DNA 
damage results in the accumulation of oncogenic mutations. Genomic 
instability is therefore a recognised hallmark of cancer (3).  
 
Cancer cells often harbor a reduced repertoire of DNA repair and DNA-
damage signalling capabilities compared to normal cells, and in some cases 
cancers also upregulate mutagenic repair pathways that drive oncogenesis 
(4). Consequently, cancer cells are often more reliant on a subset of repair 
pathways and are therefore more susceptible to DDR inhibition than are 
normal cells that maintain full DNA repair/DDR capacity. Faulty cell cycle 
checkpoint activation and suboptimal DNA repair capability in cancer cells 
also results in replication stress and subsequent accumulation of DNA 
damage in tumors. In addition, cancer cells often have dysfunctional redox 
homeostasis and therefore rely heavily on mechanisms that repair oxidative 
DNA damage, as well as on enzymes that counteract the incorporation of 
oxidised DNA precursors into genomic DNA (5,6). Both replication and 
oxidative stress, as well as other processes such as telomere attrition, provide 
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a background of ongoing DNA damage in cancer cells that can provide 
potential therapeutic windows for compounds that exacerbate these 
processes. Such compounds may achieve this by stressing replication further, 
impairing the ability of cancer cells to handle high levels of replicative or 
oxidative pressures, or potentially inhibiting DNA repair and associated 
processes (5–7). Such issues have led to intense interest in the therapeutic 
development of specific inhibitors of a range of components of the DDR 
network, several of which are now in clinical testing (8). 
 
A well-recognised sensor of DNA damage is the protein poly(ADP-ribose) 
polymerase (PARP), which is best known for its role in DNA base excision 
repair (BER) and repair of DNA single-strand breaks (SSBs; Table 1 + Figure 
1) (9), although it also has a less well-defined role in DNA double-strand 
break (DSB) repair by alternative non-homologous end-joining (alt-NHEJ; 
Table 1 + Figure 1) (10). The clinical development of PARP inhibitors in 
patients with germline BRCA1/2 mutations stemmed from the robust pre-
clinical data that demonstrated exquisite sensitivity of BRCA1/2 mutant cells 
and tumors to PARP inhibition (11,12). It was correctly hypothesised that in 
these patients, the cancer cells (in which both alleles of either BRCA1 or 
BRCA2 have been mutated or deleted) would depend on PARP activity for 
survival, whereas normal cells (that maintain a fully functional copy of BRCA1 
or BRCA2) would not. While these findings were initially thought to be due to 
a reliance of BRCA1/2 mutant cells on SSB-repair for survival, it has since 
become well-recognised that PARP trapping and the subsequent generation 
of replication-dependent DSBs also contributes significantly to the synthetic 
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lethal relationship between PARP and BRCA. In addition, the PARP family of 
enzymes plays key roles in multiple cellular processes beyond DNA repair, 
including cellular differentiation, gene transcription, inflammation, mitosis, cell 
death and metabolism, which may contribute to the antitumor activity of PARP 
inhibitors (13,14). Synthetic lethality between repair pathways has provided a 
paradigm for many current clinical strategies targeting DNA repair/DDR. 
Detailed reviews of the underlying mechanisms-of-action and clinical 
applications of PARP inhibitors have previously been published and are 
beyond the scope of this article (15–19). 
 
In this review, we summarise the current status with PARP inhibitors and then 
look beyond these, focusing on other protein components of the cellular DDR, 
which includes proteins that sense DNA damage, initiate signaling pathways 
that promote cell cycle checkpoint activation and coordinate the repair of 
damaged DNA with various other cellular processes. We highlight how such 
DDR enzymes represent rational targets for the discovery of novel 
therapeutics (Figure 1) and detail the development and future potential of 
such compounds. We also discuss the numerous challenges of discovering 
predictive biomarkers of response for optimal patient selection and the 
development of promising DDR combinations, including molecularly-targeted 
agents, compounds inhibiting epigenetic targets and immune checkpoint 
inhibitors.  
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DRUG TARGETING OF DNA DAMAGE SENSOR PROTEINS 
DDR sensor proteins detect the region of damaged DNA and direct ensuing 
cellular responses that include activation of one or more repair pathways. For 
DSBs, Ku (comprising the Ku70/Ku80 protein heterodimer) and MRN 
(MRE11-RAD50-NBS1) are the predominant sensor protein complexes. Ku 
binds DNA DSBs within seconds of them being generated, and serves as a 
platform for the subsequent recruitment of classical non-homologous end-
joining (NHEJ) proteins. The MRN complex plays key roles in triggering 
activation of the DNA-damage signalling kinase ATM, the initiation of DNA 
end-resection, and promotion of repair by HR. Chromatin context, 
transcriptional status, cell cycle stage and extent of end-resection are all 
factors that contribute to the selection of DNA repair, either by HR or NHEJ, 
and the mechanisms determining the choice of DNA repair pathway is an 
intense area of active research (20,21). Other DNA-damage sensors include 
components of the Fanconi anemia core complex (FANCA, B, C, E, F, G, L 
and M), mismatch repair proteins (MSH2, MSH3, MSH6, MLH1 and PMS2) 
and nucleotide excision repair proteins (XPC, DDB2 and CSA), which are 
sensors of DNA inter-strand crosslinks, base-base mismatches or insertion-
deletion loops and UV-induced photo-lesions (in particular cyclobutane 
pyrimidine dimers and pyrimidine 6-4 pyrimidone photoproducts), respectively 
(Table 1). 
 
There are 17 PARP family members, of which PARP-1 has the predominant 
role in DNA repair, with PARP-2 and to a lesser extent PARP-3 functioning in 
fewer, but overlapping DNA repair processes (22). Through binding to single-
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stranded DNA breaks (SSBs), DNA nicks or DSBs, PARP catalytic function is 
activated to generate extensive poly(ADP-ribose) chains (PAR chains) on 
itself and proteins in the vicinity of DNA damage. These PAR chains and 
PARP itself then promote the recruitment of critical SSB repair proteins, such 
as XRCC1 to SSBs and modify chromatin structure to facilitate DNA repair (9). 
PARP auto-PARylation is also required for the dissociation of PARP from 
DNA-damage sites (23,24). Enzymatic inhibition by PARP inhibitors therefore 
results in both the suppression of SSB repair and BER, which molecularly 
converges with SSB repair in its downstream stages. Inhibition also results in 
the trapping of PARP to SSBs, causing the stalling and subsequent collapse 
of DNA replication forks, resulting in replication-dependent DNA DSBs (23,24). 
Such DSBs would normally be repaired by HR; however in HR deficient cells, 
such as BRCA1/2 mutant tumors, less effective and lower fidelity methods of 
repair are utilised, which result in an unsustainable levels of damage, 
chromosomal fusions/translocations and ultimately cell death (20,25).  
 
Following strong preclinical findings predicting a therapeutic rationale, early 
clinical trials assessing the PARP inhibitor olaparib (Lynparza; AstraZeneca) 
demonstrated multiple durable antitumor responses in patients with advanced 
germline BRCA1/2 mutated ovarian, breast or castration resistant prostate 
cancer (CRPC) (26,27). This patient benefit was confirmed in later-phase 
clinical trials (28–31) eventually leading to clinical registration. Olaparib is now 
approved by the European Medicines Agency (EMA) as maintenance therapy 
for responding patients with BRCA1/2 mutant ovarian cancer following 
platinum-based chemotherapy. It was also granted accelerated approval by 
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the US Food and Drug Administration (FDA) for use in patients with advanced 
BRCA1/2 mutant ovarian cancers, while confirmatory trials are being 
completed. Most recently, olaparib was given breakthrough therapy 
designation for treatment of BRCA1/2 or ATM gene mutated metastatic CRPC 
in patients who have received a prior taxane-based chemotherapy and at 
least one newer hormonal agent. Another potent PARP inhibitor, rucaparib 
(Clovis), has also recently been granted breakthrough therapy status by the 
FDA following the results of the Phase II ARIEL2 trial (32) for use as 
monotherapy in patients with BRCA1/2 mutant (germline or somatic) 
advanced ovarian cancer after at least two prior lines of platinum-containing 
therapies (33). There are additional potent and selective PARP inhibitors in 
late phase monotherapy and combination clinical trial development, including 
niraparib (MK4827; Tesaro), talazoparib (BMN673; Medivation) and veliparib 
(ABT-888; Abbvie) (Table 2).  
 
Although PARP inhibition is undeniably an effective treatment for BRCA1/2 
mutated cancers, with response rates in the region of 50% for platinum-
sensitive ovarian cancers (33), the overwhelming majority of patients will 
ultimately develop tumor resistance. Genetic reversion events that restore 
BRCA1/2 gene function have been identified in PARP inhibitor resistant cell 
lines, platinum-resistant patient-derived cell lines and tumors from patients 
that have developed clinical resistance to PARP inhibitors (34). In addition, in 
Brca1-null mouse embryonic stem cells, loss of DDR factors such as 53BP1 
at least partially rescues HR by removing a barrier to DNA end-resection 
(35,36), although this has yet to be rigorously identified as a resistance 
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mechanism in the clinic. A number of critical challenges therefore remain to 
optimise the clinical efficacy and widen the utility of PARP inhibitors. 
Identifying mechanisms of PARP inhibitor resistance remains a critical 
challenge; others include the development of promising PARP inhibitor 
combination regimens and the analytical validation of clinically meaningful 
predictive biomarker assays to identify HR-deficient tumors caused by 
BRCA1/2 mutations or by other mechanisms (33).  
 
TARGETING OF DNA DAMAGE SIGNALLING PROTEINS  
By triggering various protein post-translational modifications and promoting 
the assembly of protein complexes, DDR signalling proteins amplify and 
diversify the damage signal within a cell and coordinate the most appropriate 
cellular responses, including transcriptional changes, cell cycle checkpoint 
activation, alternative splicing, engagement of DNA repair processes, or in the 
context of overwhelming damage, activation of cell senescence or apoptotic 
pathways (1). DNA DSB signalling events are largely coordinated by the 
apical phosphatidylinositol 3-kinase-related kinases (PIKKs) DNA-PKcs (DNA-
dependent serine/threonine protein kinase catalytic subunit), ATM (ataxia 
telangiectasia mutated), and ATR (ataxia telangiectasia and Rad3-related 
protein;   
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Figure 2).  
 
DNA-PK 
DNA-PKcs activity is essential for effective repair by classical NHEJ, which is 
the predominant DNA repair pathway of DSBs in human cells, occurring 
through all phases of the cell cycle (  
 12 
Figure 2A). DNA-PK is composed of Ku plus a ~460 kDa catalytic subunit 
(DNA-PKcs), the activity of which is dependent on Ku-mediated DNA DSB 
binding (37). Ku binds to DNA DSBs and serves as a platform for the 
recruitment of other core NHEJ proteins including DNA-PKcs, XRCC4, LIG4, 
XLF and PAXX amongst others (38,39). Upon DNA binding, 
autophosphorylation of DNA-PKcs induces a conformational change that 
destabilises the NHEJ core complex, causing inward sliding of Ku on the DNA 
and enabling access of end-processing and ligation enzymes to DNA ends to 
facilitate repair (37). Autophosphorylation also stimulates the dissociation of 
DNA-PKcs from DNA and Ku, and inactivates the kinase activity of DNA-PK 
(38). The best described substrate for DNA-PK is itself, with 
autophosphorylation occurring at multiple sites (37). 
 
As well as being important for the repair of exogenous DNA DSBs, classical 
NHEJ also plays crucial roles in the repair of endogenous DSBs arising during 
physiological process, such as V(D)J and class-switch recombination (40). 
Mice with a disrupted Prkdc gene have severe combined immunodeficiency, 
as well as being radiosensitive (40). In addition, DNA-PK has an established 
role in innate immunity and pro-inflammatory signalling, which are important 
issues to consider with respect to long-term treatment with DNA-PK inhibitors, 
as well as the potential for combination approaches with immune-modulating 
agents (37). Interestingly, DNA-PK has also long been known to have links to 
transcription (41), and studies are currently ongoing to investigate the 
mechanisms by which transcriptional regulation by DNA-PK affects DNA 
repair (42).  
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DNA-PK mutants lacking kinase activity, or treatment of cells with small 
molecule inhibitors of DNA-PK kinase activity cause the latter to be stabilised 
on DNA ends, impeding NHEJ and also likely interfering with other repair 
processes, including HR by obstructing DNA end-resection (38). As it plays 
key roles in repair by NHEJ, DNA-PK inhibition profoundly hypersensitises 
cells and tumor xenografts to replication-independent DSB-inducing agents, 
such as radiotherapy and topoisomerase 2 inhibitors (43). In contrast, DNA-
PK inhibition alone has very little effect on cancer cell or tumor viability (43), 
perhaps because most endogenous DSBs arise in the context of DNA 
replication, where the preferred repair pathway is HR. These compounds are 
therefore predicted to be associated with modest antitumor activity as 
monotherapy, while, there is potential for antitumor synergy in combination 
with DNA damaging agents, albeit with a potentially narrow therapeutic index 
because of associated effects on normal cells in the patient. 
 
The clinical development of DNA-PK inhibitors with high potency and 
selectivity in vitro has been complicated by inadequate pharmacokinetic (PK) 
properties. However, a number of novel DNA-PK inhibitors have recently 
entered clinical development (Table 2). For instance, MSC2490484A (Merck 
KGaA; NCT02316197) is being evaluated in phase I trials as monotherapy 
and in combination with radiotherapy, while a phase I trial of VX-984 (Vertex 
pharmaceuticals) in combination with liposomal doxorubicin has recently 
started recruitment (NCT02644278). A dual inhibitor of DNA-PK and TOR 
kinase (a downstream effector of the PI3K-AKT pathway signaling and 
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another member of the PIKK family), is CC-115 (Celgene), which was 
developed through lead optimisation of existing mTOR inhibitors (44). In pre-
clinical studies, CC-115 inhibits proliferation and induces caspase-dependant 
cell death in chronic lymphoid leukaemia (CLL) cells, and also leads to death 
of CLL cells resistant to the PI3K inhibitor idelalisib (45). The relative 
importance of DNA-PK versus TOR inhibition in this setting has however not 
been fully elucidated. In a recently reported phase I trial involving patients with 
advanced solid and hematological malignancies, CC-115 was well tolerated, 
with preliminary antitumor activity observed (46). There has been some 
suggestion that CC-115 may have greater activity in patients with CLL 
harboring biallelic ATM loss, although the mechanism for this has yet to be 
established (45).  
 
ATM 
Similar to DNA-PK, ATM promotes DNA DSB repair in cells and responds to 
DSBs generated throughout the cell cycle. Inherited mutations in the ATM 
gene result in the autosomal recessive condition Ataxia Telangiectasia, a 
syndrome characterised by progressive cerebellar ataxia, oculocutaneous 
telangiectasia, radiosensitivity, predisposition to lymphoid malignancies and 
immunodeficiency, with defects in both cellular and humoral immunity (47). A 
number of different factors have now been identified that promote ATM 
activation; however, following DNA DSBs, ATM is predominantly activated 
through interactions with NBS1 of the MRN complex (Figure 2B; (48,49). 
ATM is the principal kinase responsible for the phosphorylation of histone 
H2AX on serine 139 (known as γH2AX) (50), although some functional 
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redundancy exists with ATR and DNA-PK. MDC1 (mediator of DNA damage 
checkpoint protein-1) binds directly to γH2AX (51) and potentiates the DNA 
damage signal, leading to the spreading of γH2AX to over a megabase from 
its initial lesion (52). This amplification is thought to help sustain the DDR 
signal to enable sufficient recruitment and retention of DNA damage mediator 
proteins such as 53BP1 at sites of DNA damage, which can be visualised as 
foci in DNA damaged cells.   
 
Phospho-proteomic studies have identified hundreds of ATM substrates (53), 
although the physiological relevance of many of these proteins is currently 
unknown. A well-recognised substrate of ATM is CHK2, the activity of which is 
predominantly, but not exclusively important for G1-S phase checkpoint 
activation (54). ATM is also important for the stabilisation of p53 through the 
phosphorylation and subsequent inhibition of proteosomal degradation by 
MDM2 (54). 
 
ATM inhibition has been demonstrated to hypersensitize cells to ionizing 
radiation and the DNA DSB-inducing agents etoposide, camptothecin and 
doxorubicin (55). A phase I trial of the ATM inhibitor AZD0156 (AstraZeneca) 
is currently underway as monotherapy and in combination with olaparib and 
other cytotoxic or molecularly targeted agents (NCT02588105; Table 2). 
While there are likely to be other ATM inhibitors in development, to our 
knowledge, none have reached clinical studies. 
 
ATR 
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Although also important for DSB repair, the context for ATR activation is 
different to ATM and DNA-PK.  ATR is activated by RPA (replication protein 
A) bound ssDNA, which can arise as a result of stalled replication forks and 
also occurs following DNA end-resection during the early stages of 
homologous recombination (Figure 2C) (56). ATR is recruited to RPA-ssDNA 
by its obligate binding partner ATRIP (ATR-interacting protein), and is 
activated by TOPBP1 (topoisomerase binding partner 1) in complex with the 
Rad17-Rfc2-5 clamp loader, the 9-1-1 complex (Rad9-Rad1-Hus1), Claspin 
and RHINO (57). CHK1 is the best described substrate of ATR and once 
activated by ATR, CHK1 serves to inhibit cyclin-dependent kinase (CDK) 
activity through the phosphorylation of CDC25A. As such, CHK1 is a critical 
regulator of the G2-M and intra-S cell cycle checkpoints (Figure 2C) (58). 
Interestingly, recent preclinical studies have demonstrated that both ATR and 
CHK1 have distinct roles in the regulation of the intra-S checkpoint. ATR 
appears particularly important for the suppression of replication catastrophe in 
early S-phase cells through the promotion of ribonucleotide reductase 
accumulation and by limiting origin firing (59). In contrast, other S-phase cells 
are capable of recovering from replication insults through a CHK1-mediated 
back-up mechanism (59). A synthetic lethal relationship has now been 
established between ATR and CHK1 inhibition, with combination blockade 
leading to replication fork arrest, DNA SSB accumulation, replication collapse 
and synergistic cell death in cancer cells in vitro and in vivo (60).  
 
In addition, a third checkpoint kinase has now been identified (MK2; 
MAPKAP-K2), which functions independently of CHK1, downstream of ATM 
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and ATR to maintain G2/M and intra-S phase arrest (61–63). To our 
knowledge, there are currently no MK2 inhibitors in clinical development, 
although pre-clinical work has demonstrated interesting synergy between 
MK2 and CHK1 inhibitors, particularly in KRAS mutant tumors (64). 
 
VX-970 (Vertex pharmaceuticals) is a first-in-class ATR inhibitor, with 
preclinical data demonstrating chemosensitization of lung cancer cells 
predominantly to chemotherapeutics that result in replication fork collapse, 
such as cisplatin and gemcitabine in vitro, and increased antitumor activity in 
combination with cisplatin in vivo (65,66). Preliminary phase I trial data have 
shown that VX-970 is well tolerated as monotherapy with no dose limiting 
toxicities or grade 3-4 adverse events demonstrated up to weekly intravenous 
(IV) doses of 480mg/m2 (67). A durable RECIST (response evaluation criteria 
in solid tumors) complete response was observed in a patient with metastatic 
ATM-loss colorectal cancer, who remained on single agent VX-970 for more 
than 20 months. When VX-970 was combined with carboplatin, although the 
maximum tolerated dose was not established, because there was no more 
than 1 dose-limiting toxicity at each dose level, the recommended phase II 
dose (RP2D) was VX-970 90 mg/m2 + carboplatin area under the curve (AUC) 
5 based on carboplatin dose delays observed at higher dose levels. Crucially, 
paired tumor biopsy studies undertaken at this RP2D showed significant 
inhibition of ATR-targeted phosphorylation of Ser-345 on CHK1, confirming 
target modulation. At the RP2D, a patient with platinum-refractory, PARP 
inhibitor resistant, germline BRCA1 and TP53 mutant advanced high-grade 
serous ovarian cancer achieved a RECIST partial response and gynecologic 
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cancer intergroup (GCIG) CA125 tumor marker response lasting 6 months. As 
expected from the predicted mechanism-based toxicity profile of an ATR 
inhibitor and platinum chemotherapy, myelosuppression (neutropenia and 
thrombocytopenia) was the most commonly observed treatment-related 
toxicity (68). Combination trials with VX-970 and a number of other 
chemotherapeutics are ongoing, including cisplatin and gemcitabine, with 
promising antitumor responses observed in chemotherapy-resistant patients 
with advanced solid cancers (69,70) ( Table 2). AZD6738 (AstraZeneca) is an 
oral ATR inhibitor currently being assessed in phase I clinical trials as 
monotherapy or in combination regimens with olaparib, carboplatin, 
radiotherapy or the immune-checkpoint inhibitor durvalumab (MEDI4736; 
AstraZeneca). The optimal scheduling and sequencing of these agents with 
their respective partners, in order to balance the trade-off between antitumor 
activity and bone marrow toxicity, is not yet clear and full results of these trials 
are awaited with interest. 
 
CHK1 
Pre-clinically, CHK1 inhibitors have demonstrated most synergy with drugs 
that generate replication dependent DNA damage such as anti-metabolites, 
and therefore clinical development has focused on their use in combination 
with such drugs (71). MK8776 (Merck & Co) is a potent and selective CHK1 
inhibitor that is well tolerated as a monotherapy, as well as in combination 
with gemcitabine (Table 2) (72). Results from a recently published phase I 
trial of MK8776 as monotherapy or in combination with gemcitabine, has 
shown preliminary evidence of clinical efficacy, with 2/30 patients (7%) having 
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a partial response and 13/30 (43%) demonstrating stable disease (72). As 
expected, toxicity was more frequent in combination, and included fatigue, 
nausea, anorexia, thrombocytopenia, neutropenia and transient, dose-related 
electrocardiogram (ECG) abnormalities, specifically QTc prolongation. The 
recommended phase II dose of MK8776 is 200mg, with gemcitabine 
administered at 1000 mg/m2 on days 1 and 8 of a 21-day cycle. LY2603618 
(Eli Lilly) is a selective CHK1 inhibitor being evaluated at both 170mg and 
230mg in combination with gemcitabine (Table 2) (73). Preliminary results 
reported RECIST partial responses in 4/17 patients, with mainly hematological 
toxicities observed, and three patients discontinuing treatment because of 
adverse events. A phase I trial of CHK1 inhibitor CCT245737 (Sareum 
Holdings plc) as monotherapy, and in combination with cisplatin and 
gemcitabine has recently started accrual (NCT02797977, NCT02797964) 
(Table 2). 
 
CHK2 
There is some uncertainty as to whether the inhibition of CHK2 will be 
beneficial in the clinical setting, and at present there are no selective CHK2 
inhibitors in clinical development (71). Genetic deletion of the mouse Chek2 
gene alleviates p53-dependent cell death following irradiation and although 
the mechanisms for this protection have not been fully defined, there is a 
hypothetical risk that inhibition of CHK2 may be radio-protective in a clinical 
setting (74). Further studies are required to determine the appropriate clinical 
context in which CHK2 inhibition may lead to antitumor activity (75). Several 
of the early cell cycle checkpoint inhibitors, such as LY2606368 (Prexasertib; 
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Eli Lilly), are dual inhibitors of CHK1 and CHK2, and many of these have now 
discontinued clinical development due to lack of efficacy. LY2606368 has 
undergone evaluation in a phase I trial, defining a RP2D of 105mg/m2 every 
14 days, with a predominant toxicity of myelosuppression (Table 2) (76). 
Evidence of single agent activity was observed, with 2/45 patients achieving a 
RECIST partial response (one with anal cancer and one with head and neck 
squamous cell carcinoma), while 15/45 (33.3%) patients obtained clinical 
benefit with radiological stable disease. The trial is expanding, preferentially in 
patients with squamous histology tumors, and several combination strategies 
are currently ongoing.  
 
WEE1 
Working in parallel with CHK1, the WEE1 protein kinase also plays a critical 
role in the activation of the G2-M checkpoint through the regulation of cyclin 
dependent kinases (77,78). Unlike CHK1, however, WEE1 is not directly 
regulated by DNA damage, but is required for physiological cell cycle 
progression. CDK1 Tyr15 phosphorylation by WEE1 inhibits CDK1 activity 
resulting in inactivation of the CDK1/CCNB1 complex and G2-M checkpoint 
activation (79). The predominant mechanism-of-action of WEE1 inhibitors was 
initially believed to be failure of the G2-M checkpoint due to inappropriate 
CDK1/CCNB1 activation, resulting in mitotic catastrophe (79). More recently, 
however, it has become clear that WEE1 inhibition also generates replication-
dependent DNA damage in cells, due to aberrant DNA replication through 
CDK2 inhibition (80,81). The first-in-class WEE1 kinase inhibitor AZD1775 
(MK1775; AstraZeneca) has been shown to potentiate the cytotoxic effects of 
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a range of DNA damaging agents and demonstrate single agent activity In 
preclinical models (77). AZD1775 has been evaluated in a single agent phase 
I clinical trial (82), where a maximum tolerated dose of 225mg twice daily for 
2.5 days per week for two weeks in three-weekly cycles was established 
(Table 2). Dose limiting toxicities reported were reversible supraventricular 
tachycardia and myelosuppression, with common toxicities including 
myelosuppression and diarrhea. The study noted evidence of single agent 
activity with RECIST partial responses in two germline BRCA1 mutant 
patients (papillary serous ovarian and squamous cell carcinoma of the head 
and neck). Proof-of-mechanism target modulation was demonstrated in paired 
tumor biopsies demonstrating reduced CDK1 Tyr15 phospho levels and 
increased γH2AX levels after treatment. 
 
Recently published data from a phase I trial of AZD1775 in combination with 
gemcitabine, cisplatin or carboplatin demonstrated that chemotherapy 
combinations with AZD1775 were safely tolerated, with superior response 
rates in TP53-mutated (21%) compared to TP53 wild-type patients (12%) (83). 
Interestingly, there is also evidence that WEE1 inhibition may reverse 
platinum resistance, as the combination of AZD1775 and carboplatin has 
shown antitumor activity in patients with TP53 mutant, platinum 
resistant/refractory ovarian cancer, with a published RECIST partial response 
rate of 38% (n=8) and complete response rate of 5% (n=1) (Table 2) (84). 
Preliminary data from a phase II trial of AZD1775 in combination with 
carboplatin and paclitaxel versus chemotherapy alone in patients with 
platinum-sensitive TP53-mutant ovarian cancer demonstrated a superior 
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progression free survival (PFS) benefit [hazard ratio (HR) 0.55, CI 0.32-0.95, 
p=0.030], with common toxicities including nausea, diarrhea, alopecia and 
fatigue (Table 2) (85). There is now a need to better define the patient 
populations predicted to respond to AZD1775 monotherapy and novel 
combination regimens, and numerous biomarker-driven clinical trials with 
AZD1775 are currently ongoing to address such issues (Table 2). 
 
TARGETING DDR EFFECTOR PROTEINS AND REPAIR PATHWAYS  
DDR events converge on one or more repair pathways that are dedicated to 
specific types of DNA damage (Figure 1 and Table 1). Some established 
antitumor agents result in a single type of DNA lesion (e.g. topoisomerase 
inhibitors), while others generate a heterogenous mixture of DNA damage 
types, engaging multiple repair pathways simultaneously (e.g. radiotherapy). 
While NHEJ and HR remain the predominant DSB repair pathways, the 
importance of alternative homology-directed repair mechanisms is also now 
recognised (20). These are mutagenic pathways that are able to ‘back-up’ 
standard repair processes, which have either been genetically or chemically 
compromised. While there are multiple attractive DNA repair and DDR 
effector protein targets, there are still only a limited number of drugs currently 
in clinical development that target such proteins.  
 
APE1 (AP endonuclease-1) recognises abasic (AP) sites generated following 
the removal of damaged bases by DNA glycosylases, and its endonuclease 
activity is essential for BER (86). In addition, APE1 harbors exonuclease 
activity important for the removal of 3' obstructive lesions in DNA, including 
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chain-terminating nucleoside analogs (87). TRC102 (Methoxyamine; 
TRACON pharmaceuticals) reacts with abasic sites to cause an AP-adduct 
that is resistant to APE1 action (88), exacerbating the cytotoxicity of alkylating 
agents and anti-metabolites in cells. Hematological toxicities were dose 
limiting for TRC102 in combination with pemetrexed or temozolomide (89,90), 
and other early phase combination trials are ongoing (Table 2). 
 
Recent studies have demonstrated that HR deficient cells rely on error-prone 
microhomology-mediated end-joining (MMEJ; also known as alt-NHEJ) for 
survival (25,91). The polymerase activity of POLQ (DNA polymerase theta) is 
required for gap-filling during MMEJ, and POLQ also prevents hyper-
recombination by limiting RAD51 accumulation at resected DNA ends (25,91). 
POLQ is therefore an attractive drug target, particularly in the context of HR 
deficient tumors. The development of small molecule inhibitors that target 
protein-protein interactions of the RAD51 recombinase family are also 
ongoing (92). Targeting protein-protein interactions is challenging and has 
had limited success, although compounds have been identified that disrupt 
the self-association of RAD51 and successfully inhibit the interaction between 
RAD51 and BRCA1 (92). These compounds have the potential to inhibit 
RAD51-dependent HR in cells, and the demonstration of such effects in 
functional cellular assays is awaited. 
 
FINE-TUNING THE DDR 
Each step of the DDR is tightly regulated by reversible post-translational 
modifications (PTMs) including: phosphorylation, ADP-ribosylation, 
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methylation, acetylation, ubiquitylation, sumoylation and neddylation (93–96). 
While DDR-specific kinase and ADP-ribosylation inhibitors are already in 
clinical development/use, given the essential role of ubiquitylation and de-
ubiquitylation in the DDR, modulating DNA repair through the use of specific 
inhibitors of ubiquitylation, deubiquitylation or the ubiquitin-proteasome 
system is an active area of research (96,97). HR is particularly sensitive to 
proteasome inhibition (98) and proteasome inhibitors such as bortezomib 
(Velcade; Takeda Pharmaceutical Company Ltd) have been shown to block 
global ubiquitylation in cells, and disrupt protein turnover of several DDR 
proteins, such as MDC1, BRCA1 and RPA (99–101). Inhibiting a subset of 
ubiquitin ligases, namely the cullin-ring-ligases (CRLs), through inhibition of 
neddylation (the covalent attachment of the ubiquitin-like protein, NEDD8 to 
target proteins) in cells, also affects the DDR (93,102). Pevonedistat 
(MLN4924; Takeda Pharmaceutical Company Ltd) inhibits the NEDD8 E1, 
blocking NEDD8 conjugation and CRL activity in cells (103). A phase I study 
of pevonedistat showed that an intermittent dosing schedule was generally 
well tolerated, with hepatotoxicity being dose-limiting (104). In pre-clinical 
studies, pevonedistat exhibited particular synergy with DNA cross-linking 
agents (105,106) and phase I combination studies are currently ongoing.  
 
PTMs are reversible, with such turnover being important for various cellular 
processes. It’s perhaps unsurprising therefore that deubiquitylating enzymes 
(DUBs) also play key roles in promoting DNA repair in cells. Indeed, various 
DUBs are attractive drug targets (96), with several DUB inhibitors currently in 
pre-clinical development. Analogously, poly(ADP-ribose) glycohydrolase 
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(PARG) catalyses the hydrolysis of poly(ADP-ribose) and therefore reverses 
the effects of PARP. Inhibition of PARG, in a similar fashion to PARP 
inhibition, leads to DNA damage that depends on HR for repair (107), and 
efforts are ongoing to generate specific PARG inhibitors for clinical use (108). 
 
Several other classes of compounds have demonstrated inhibitory effects on 
the DDR, which may potentially be exploited in a clinical setting. Chromatin 
compaction significantly affects DNA repair (21) and the chromatin modifying 
inhibitors vorinostat (ZolonzaTM; Merck) and romidepsin (Istodax; Celgene) 
are both approved for the treatment of cutaneous T cell lymphoma (109). As 
well as relieving chromatin compaction, these histone deactylase (HDAC) 
inhibitors also transcriptionally down-regulate a number of DSB repair proteins, 
thereby hypersensitising cells to DSB-inducing agents and providing strong 
rationale for combination treatment with DNA-damaging compounds 
(110,111). There are numerous other compounds in pre-clinical and clinical 
development, which have inhibitory effects on DNA repair through targeting 
epigenetic modifier enzymes, such as EZH2 (H3K27 methyltransferase) (112), 
histone deacetylases (HDACs) (111) and G9A (histone lysine N-methyl-
transferase) (113). 
 
PATIENT SELECTION  
PARP inhibitors are selectively toxic to tumor cells with biallelic mutations/loss 
of BRCA1 or BRCA2 (BRCA1/2) (11,12), and olaparib is the first oncology 
drug to be licensed with a companion genetic diagnostic (BRCAnalysis 
CDxTM). Such a level of “synthetic lethality” has yet to be reproduced with any 
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other DDR inhibitor. The effectiveness of PARP inhibitors is not restricted to 
patients with germline or somatic BRCA1/2 mutations however, and 
significant efforts are underway to determine tumors that are essentially HR 
deficient through other mechanisms (15). Genomic approaches to achieve 
this include studies undertaken to identify mutations in single HR and/or other 
genes that predict for PARP inhibitor sensitivity (114,115). In addition, DNA 
repair dysfunction has the potential to lead to global DNA aberrations; the 
presence of a genome-wide mutational signature (or genomic scar) that 
occurs in the context of chronic HR deficiency, may thus also be a useful 
biomarker that is predictive of PARP inhibitor sensitivity (116). Scoring 
systems that measure genomic defects reflective of HR deficiency are also 
being utilised, including those that quantify loss of heterozygosity (LOH), 
telomeric allelic imbalance and large scale state transitions (defined as a 
chromosomal break between adjacent segments of DNA of at least 10 Mb) 
within tumors (117).  
 
The hypermethylation of genes and other epigenetic effects mean that 
focusing entirely on genomics will ultimately fail to identify all patients who are 
likely to benefit from a molecularly-targeted cancer therapy. To address this 
issue, functional assays of HR deficiency have been pursued and have 
included the detection of RAD51 foci at DNA-damage sites in breast cancer 
biopsies following neo-adjuvant chemotherapy, where a failure to generate 
RAD51 foci in cells was strongly predictive of a pathological complete 
response (p=0.011) (118). To date, however, there is no robust strategy to 
clinically determine which patients will benefit from PARP inhibitors outside of 
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the BRCA1/2 mutant population and it may be that a combination of functional 
and genomic approaches is required. 
 
Beyond PARP inhibitors, preclinical data have demonstrated synergy between 
ATR inhibition and impaired ATM signalling, particularly in the context of 
exogenous DNA damage (119). The mechanism for this synergy has yet to be 
defined; however, clinical studies exploring ATR inhibition in the context of 
ATM loss are ongoing (68). Certainly, a number of studies suggest that high 
levels of replication stress and consequently, increased endogenous DNA 
damage in tumors may be required for hypersensitivity to ATR inhibitor 
monotherapy. Overexpression of oncogenes such as CCNE1, CCND2 and 
MYC, adversely affects DNA replication by disrupting origin firing and 
replication progression, resulting in oncogene-induced replication stress (7). 
In keeping with this, CCNE1 amplification exaggerates the hypersensitivity of 
TP53 deficient cells to ATR inhibition (120), and both ATR and CHK1 
inhibitors are particularly toxic for Myc-driven lymphomas in mice (121). In 
addition, oncogenic stress as a result of activating KRAS mutations has been 
shown to hypersensitise cells to ATR inhibition (122), and selecting tumors 
with oncogene-induced replication stress has the potential to provide a much-
needed therapeutic window for ATR inhibitor/chemotherapy combination 
strategies. 
 
The physical ends of linear chromosomes, telomere ends, are naturally 
occurring DNA DSBs in cells that are protected by the Shelterin protein 
complex in order to prevent DDR activation (123). Maintaining telomere length 
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is essential for the genomic stability of replicating cells and involves the 
concerted actions of several key DDR players, including ATM, ATR, DNA-PK 
and Ku (124,125). Telomere maintenance is achieved through telomerase 
activation in 85% of cancers and telomerase recruitment to telomeres is 
dependent on ATM and ATR activity in human cells (125). ATR activity has 
also been shown to be important for alternative lengthening of telomeres 
(ALT) (126), a mechanism which relies on recombination events to maintain 
telomere length. In keeping with this, preclinical data have been published 
demonstrating hypersensitivity of ALT tumor cells to ATR inhibition (126). 
Given the role of the DDR PIKKs in telomere maintenance, DNA-PK, ATM 
and ATR inhibitors, all have the potential to negatively affect telomere length 
in cells. While this may potentially contribute to their antitumor effects, it may 
also result in detrimental genomic instability in replicating non-cancer cell 
populations. 
 
It is currently too preliminary to establish if TP53 deficiency, ATM 
loss/mutation, ALT reliance or CCNE1, CCND2 or MYC oncogene activation 
will predict for sensitivity to ATR inhibitors in the clinic, but it is likely that this 
will be a far from exhaustive list of putative genomic predictive biomarkers, 
and having a functional marker of replication stress in tumors will be helpful. 
Surrogate markers of replication stress might include phosphorylation of ATR 
substrates (e.g. CHK1pS345 and RPApS33) or levels of single-stranded DNA 
(59). How these markers might change over time and with treatment is of 
course currently unknown however, and the usefulness of measuring these 
biomarkers in archival tumor specimens has yet to be tested. 
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COMBINATION STRATEGIES  
Combining DDR inhibitors with DNA damaging agents has been the natural 
first step in the clinical development of combination strategies for DDR 
inhibitors (Table 2). A thorough understanding of the DNA lesions induced by 
different chemotherapies, and inhibition of the respective pathways required 
for repair will ultimately maximise the odds of synergistic antitumor efficacy. 
Nevertheless, toxicities will in many cases likely limit drug doses used in such 
combinations. Indeed, combining olaparib with carboplatin and paclitaxel 
chemotherapies in the clinic has been challenging because of 
myelosuppression, and reductions in the full single-agent doses of all drugs 
had to be undertaken to enable the combination to be administered safely 
(127,128). While olaparib showed promising data in a phase II trial of patients 
with advanced gastric cancer harboring ATM loss when combined with the 
paclitaxel chemotherapy (129), there was no statistically significant survival 
benefit in the phase III GOLD trial (according to a May 18th, 2016 
AstraZeneca press release). Optimizing drug scheduling may enable potential 
differences in repair kinetics of normal versus cancer cells to be exploited and 
may therefore, increase damage in tumors while sparing normal tissue. 
Careful consideration of the sequence of combination drug administration is 
required to optimize synergistic effects. Equally, selecting patients with tumors 
of specific genotypes or phenotypes may produce a therapeutic window for 
such combinations. 
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Combining DDR inhibitors with small molecule inhibitors of other cellular 
signalling pathways also shows promise, and PARP inhibition has been tested 
in combination with a number of agents. For example, an EGFR inhibitor 
combination has been explored following clinical data from the EURTAC trial 
showing that low BRCA1 mRNA levels were associated with longer PFS to 
erlotinib (Tarceva; Genentech) (130). A phase I trial of olaparib with gefitinib 
(Iressa; AstraZeneca) demonstrated safety and tolerability, as well as 
promising signals of antitumor activity (131); a phase 2 trial is now accruing 
(132). Recent pre-clinical data also suggest that inhibition of the receptor 
tyrosine kinase c-MET hypersensitises cells to PARP inhibition and the clinical 
evaluation of this finding is likely to follow (133). Preclinical evidence of 
phosphatidylinositide 3-kinase (PI3K) inhibition impairing BRCA1/2 expression 
and sensitising tumor cells to PARP inhibition in both BRCA1/2-mutant and 
BRCA1/2-wild type breast cancers (134,135) has led to phase I combination 
trials of olaparib with the PI3K inhibitor BKM120 (Buparlisib; Novartis) (136) 
and the AKT inhibitor AZD5363 (AstraZeneca) (137), respectively. Preliminary 
data suggest that these combinations are tolerable and effective, with final 
results awaited with interest. 
 
Preclinical evidence suggests that hypoxia results in impaired HR through the 
down-regulation of HR-related genes (138–140). This provided the rationale 
for a phase 1/2 trial of the pan-vascular endothelial growth factor (VEGF)1-3 
inhibitor cediranib (AZD2171; AstraZeneca) with olaparib in patients with 
platinum-sensitive ovarian cancer (141). A PFS benefit of 8.7 months (HR 
0·42 [95% CI 0·23–0·76; p=0·005]) was demonstrated with the combination 
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versus olaparib alone in the overall patient population, with predominant 
toxicities of fatigue, diarrhea and hypertension in the combination arm 
observed. Interestingly, however, no PFS difference was observed between 
the two treatment arms in patients with BRCA1/2 mutated ovarian cancer. 
 
Apart from molecularly targeted agents, we are also beginning to appreciate 
the considerable crosstalk between DNA repair and endocrine signalling (142). 
Steroid hormone signaling has been shown to promote NHEJ through 
transcriptional regulation of NHEJ components such as PRKDC, and has 
been demonstrated to have both positive and negative effects on HR 
depending on tumor model and context (142). In prostate cancer models, 
PARP1 has been demonstrated to support androgen transcriptional function, 
and is required for transcriptional activation of the oncogenic fusion 
TMPRSS2-ERG protein found in >50% of prostate cancers. Duel blockade of 
PARP activity and androgen receptor signaling delays tumor growth 
compared to either as monotherapy in mouse xenograft prostate cancer 
models (143). This has led to trials combining PARP inhibitors with hormonal 
manipulation, such as olaparib with the CYP17 inhibitor abiraterone (Zytiga; 
Janssen Biotech) (144).  
 
There are also now multiple combination studies involving immune checkpoint 
inhibitors with DDR inhibitors, such as PARP and ATR inhibitors (Table 2). 
There is pre-clinical evidence to suggest that immune checkpoint inhibition 
synergizes with PARP inhibitor treatment in BRCA1 deficient tumors and 
clinical trials investigating this hypothesis are ongoing (145). In addition, the 
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success of anti-PD-1/PD-L1 therapeutics in MMR deficient tumors (146) 
raises the intriguing question as to whether increasing mutational load with 
DDR inhibitors might increase the immunogenicity of cancers and subsequent 
responses to immunotherapy. Further studies are required to substantiate this 
hypothesis, and while high levels of microsatellite instability might prove to be 
a useful biomarker of response to immune checkpoint inhibitors, alternative 
mechanisms that might be driving sensitivity should not be discounted (147). 
Equally, we must be mindful that an intact DDR plays an important role in 
innate immunity (148). DDR signalling is important for the activation of 
inflammatory cytokines and induces the expression of immune-receptor 
ligands on damaged cells. As such, inhibitors of DDR signalling may in fact 
attenuate the immune response following DNA damage and therefore 
immunotherapy-DDR inhibitor combination studies need to be carefully 
considered.  
 
FUTURE PERSPECTIVES AND CONCLUSIONS 
With multiple DDR inhibitors now in preclinical and clinical pipelines, careful 
consideration of their mechanisms-of-action is required in order to maximise 
their potential. DDR-deficient tumors should not be grouped indiscriminately 
into a class of tumors that may respond to any DDR inhibitor. Through closer 
collaborations between scientists and clinicians, we must insist on a rational 
rather than empirical approach to the clinical development of DDR inhibitors. 
A number of factors will be critical to ensure clinical success, including the 
development of analytically validated pharmacodynamic assays and 
predictive biomarkers of response and resistance. As we have observed with 
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PARP inhibitors, managing the toxicities of DDR inhibitor/DNA-damaging 
agent combinations is likely to be challenging, and so clinicians should not 
shy away from aiming for a single agent synthetic lethal approach that has 
already led to some success in the clinic. Much attention has focused on 
genetic alterations to key DDR drivers, but the relative contribution of somatic 
epigenetic loss of such DDR players has not been extensively explored. For 
example, the silencing of the BRCA1 gene through promoter 
hypermethylation has been demonstrated in breast and ovarian cancers (149), 
which highlights the importance of also considering functional biomarker 
assays, rather than relying on genomics in isolation.  
 
Modern clinical trial designs will need to incorporate translational studies, 
which may be used to guide patient selection, drug scheduling and treatment 
response (150). Early phase trials should aim to consolidate preclinical 
understandings of drug mechanisms-of-action. Notably, understanding how 
many successful drugs function, including the PARP inhibitors, has changed 
over time, meaning that compounds showing preclinical promise should not 
be discounted on the basis of hypotheses that later appear to be incorrect. It 
is likely that combination regimens, either with drugs given together or 
sequentially to overcome resistance, will be required for the optimal 
application of these DDR inhibitors in the clinic. The use of longitudinal 
genomic profiling of circulating free DNA to support adaptive drug 
administration will also be important. 
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The long-term effects of inhibiting the DDR in patients are still not known and 
needs further study. One recognised risk of DNA damage to normal tissue is 
the emergence of secondary cancers, particularly hematological malignancies, 
following chemotherapy treatment and the potential mutagenic effects of 
inhibiting DNA repair. We will need to increase our clinical experience of DDR 
inhibitors before the long-term effects of these compounds are realised. 
Nevertheless, as PARP inhibitors move into the neo-adjuvant and adjuvant 
settings, the malignant potential of these drugs must be monitored. 
 
Precision medicine has heralded the advent of sophisticated modern 
technologies, which have permitted genomic profiling of both normal and 
tumor tissue at greater speeds and at lower costs than before. This has 
enabled the “real-time” identification of germline and somatic DNA repair gene 
aberrations, which has critical implications both for identifying families at risk 
of cancer predisposition, and also for predicting therapeutic responses to 
DDR inhibitors. Now that olaparib has been approved for clinical use and 
others will hopefully soon follow, we must not forget the lessons learned from 
the successful development of PARP inhibitors, nor ignore the multitude of 
opportunities that still exist within the DDR network, which now need to be 
exploited to impact positively on cancer medicine.  
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Double strand break repair pathways 
Classical (c)-
NHEJ 
 
 Predominant DNA DSB repair pathway in human cells, functioning throughout the cell cycle. 
 Involves the relatively rapid ligation of broken DNA ends, mediated by the core NHEJ complex 
including, DNA-PK, XRCC4, LIG4, XLF and PAXX amongst others.  
 DNA end-processing and DNA polymerase action may be required before ligation can occur, making 
NHEJ inherently error-prone. 
 NHEJ maintains genome stability however, by rapidly repairing DSBs in circumstances where 
recombinogenic events would likely result in gross chromosomal rearrangements; in non-cycling or 
G1 cells for example (38,39). 
Homology-directed repair  
Homologous 
recombination 
(HR) 
 Relatively slow and restricted to late-S phase/G2 as it generally relies on a homologous sister 
chromatid DNA strand for repair.  
 Extensive DNA end-resection by helicases and exonucleases such as DNA2, BLM, WRN and EXO1 
results in a 3′ –ssDNA overhang, committing the break to repair by HR.   
 RPA coats and stabilizes the ssDNA, leading to ATR activation and subsequent signaling events. 
 BRCA2, with the help of BRCA1 and PALB2, load RAD51 onto the RPA-coated ssDNA leading to 
strand invasion, with a number of factors negatively regulating this process to prevent hyper-
recombination such as POLQ, PARI, RECQL5, FANCJ and BLM (151). 
Alternative 
(Alt)- NHEJ or 
microhomology 
mediated end-
joining (MMEJ) 
 Ligation pathway for DSBs when c-NHEJ is genetically compromised (152). 
 Occurs following limited DNA end resection.  
 Contributes to the excessive genomic deletions and chromosomal translocations seen in tumors and 
may also provide a back-up repair pathway in HR deficient cells (10,20). 
Single-strand 
annealing 
(SSA) 
 Mutagenic, RAD51 independent repair pathway, involving annealing of short or longer complimentary 
DNA sequences on resected DNA with subsequent deletion of the intervening DNA sequence. The 
detailed mechanism has yet to be defined in mammalian cells (20). 
Other repair pathways 
Inter-strand 
crosslink (ICL) 
repair  
 ICLs cause DNA replication fork stalling and collapse, resulting in DNA DSBs.   
 ICLs are recognised by the FANCONI core complex, which engages HR, TLS and NER pathways to 
repair the DNA lesion (153). 
Single-strand 
break (SSB) 
repair  
 SSBs usually arise following the removal of a damaged nucleotide (154). 
 PARP1 (poly-ADP-ribose polymerase 1) is the DNA damage sensor protein for DNA strand breaks.  
PARP1 localises to sites of DNA damage, generating extensive PAR (poly ADP-ribose) chains. 
 Ribosylated PARP1 promotes recruitment of SSB-repair proteins to DNA damage sites (9). 
Base excision 
repair (BER) 
 DNA glycosylases recognize and remove damaged bases leading to basic sites that are processed 
by APE1 (AP-endonuclease 1).  
 Results in SSB generation, repaired using SSB repair pathways (86). 
Tran-lesion 
synthesis (TLS) 
 DNA damage tolerance pathway that helps prevent replication fork stalling (155). 
 Engages low-fidelity DNA Y-family polymerases (e.g. REV1, POLH, POLI, POLK) that accommodate 
the damaged lesion, replicating past it, at the expense of increased mutagenesis.  
Nucleotide 
excision repair 
(NER) 
 Removes helix-distorting lesions from DNA, in particular the UV-induced photo lesions. 
 Involves removal of a short oligonucleotide including the damaged lesion using structure specific 
endonucleases and subsequent restoration of the DNA sequence by DNA polymerases (156). 
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Mismatch 
repair (MMR) 
 MSH2, MSH3 and MSH6 recognize base-base mismatches and IDLs, where they recruit MLH1 and 
PMS2 to damaged sites.  The concerted actions of the mismatch repair proteins, engage EXO1 to 
remove the mismatch and then POLD and LIG1 to fill the gap and seal the nick respectively (157). 
 
Table 1: Predominant DNA repair pathways. 
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Target Agent Phase Intervention Cancer(s) enrolled Status / results Trial identifier Ref. 
DNA-PK MSC2490484A I MSC2490484A Solid tumors, CLL Recruiting NCT02316197 - 
 MSC2490484A I MSC2490484A ± RT Solid tumors Recruiting NCT02516813 - 
 VX-984 I VX-984 ± PLD Solid tumors Recruiting NCT02644278 - 
 CC-1151  I CC-115 GBM, HNSCC, Prostate, ES, CLL 
37% (3/8) PR in relapsed 
ATMmut CLL 
NCT01353625 (45,46) 
ATM AZD0156 I AZD0156 ± olaparib Solid tumors Recruiting NCT02588105 - 
ATR 
VX-970 ± 
chemotherapy 
I VX-970 ± carboplatin Solid tumors Recruiting 
EudraCT: 2013-
005100-34 
(67,68) 
  I 
VX-970 ± gemcitabine, 
etoposide, cisplatin or 
carboplatin 
Solid tumors Recruiting NCT02157792 (69,70) 
  II 
Gemcitabine ± VX-970 
(randomised) 
Ovarian, primary peritoneal or 
Fallopian tube 
Recruiting NCT02595892 - 
  I VX-970 + irinotecan Solid tumors Recruiting NCT02595931 - 
  II 
Carboplatin + gemcitabine 
± VX-970 (randomised) 
Advanced gynecologic cancers Not yet recruiting NCT02627443 - 
  I / II VX-970 + topotecan 
Advanced NSCLC, SCLC, 
Gynae or neuroendocrine 
Recruiting NCT02487095 - 
  II 
Cisplatin + gemcitabine ± 
VX-970 (randomised) 
Advanced urothelial  Recruiting NCT02567409 - 
 VX-970 ± RT I Cisplatin + RT ± VX-970 Locally advanced HNSCC Recruiting NCT02567422 - 
  I Whole brain RT + VX-970 NSCLC brain metastases Recruiting NCT02589522 - 
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VX-970 + 
targeted therapy 
I 
VX-970 + veliparib + 
cisplatin 
Solid tumors Recruiting NCT02723864 - 
 AZD6738 I AZD6738 
Relapsed CLL, PLL, B cell 
lymphomas 
Complete, full results awaited NCT01955668 - 
 
AD6738 ± 
chemotherapy 
I 
AZD6738 ± carboplatin, 
olaparib or MEDI4736  
Solid tumors, HNSCC, ATMloss 
NSCLC, gastric or GOJ carcinoma 
Recruiting NCT02264678 - 
  I AZD6738 + paclitaxel Solid tumors Recruiting NCT02630199 - 
 AZD6738 + RT I AZD6738 + palliative RT Solid tumors Recruiting NCT02223923 - 
CHK1 
MK8776  
(SCH 900776) 
II 
Cytarabine ± MK8776 
(randomised) 
Relapsed AML Complete, full results awaited NCT01870596 - 
  I Gemcitabine + MK8776 Relapsed lymphoma Complete, full results awaited NCT00779584 (72) 
  I Cytarabine + MK8776 Relapsed AML 33% (8/24) CR NCT00907517 (158) 
 LY2603618 I / II 
Cisplatin / pemetrexed ± 
LY2603618 
NSCLC 14% (2/14) PR NCT01139775 (159) 
  I / II Gemcitabine ± LY2603618 Pancreatic carcinoma Complete, full results awaited NCT00839332 - 
  II Pemetrexed + LY2603618 NSCLC Complete, full results awaited NCT00988858 - 
  I 
LY2603618 + pemetrexed 
or gemcitabine 
Solid tumors Complete, full results awaited NCT01296568 - 
  I LY2603618 + gemcitabine Solid tumors Complete, full results awaited NCT01341457 (73) 
  I LY2603618 + pemetrexed Solid tumors Complete, full results awaited NCT00415636 - 
 CCT245737 I CCT245737 Solid tumors Recruiting NCT02797964 - 
  I 
CCT245737 + cisplatin 
and/or gemcitabine 
Solid tumors Recruiting NCT02797977 - 
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GDC-0575 ± 
chemotherapy 
I GDC-0575 ± gemcitabine 
Solid tumors, relapsed 
lymphoma 
Complete, full results awaited NCT01564251 - 
CHK1/2 LY2606368 II LY2606368 Refractory SCLC  Recruiting NCT02735980 - 
  II LY2606368 Ovarian, breast, prostate Recruiting NCT02203513 - 
  II LY2606368 Solid tumors Recruiting NCT02873975 - 
  I LY2606368 Solid tumors 
4% (2/45) PR – anal SCC, 
HNSCC 
NCT01115790 (76) 
  I LY2606368 Solid tumors Recruiting NCT02778126 - 
  I LY2606368 Solid tumors Recruiting NCT02514603 - 
  I LY2606368 Pediatric solid tumors Recruiting NCT02808650 - 
 
LY2606368 + 
chemotherapy 
I 
LY2606368 + fludarabine 
+ cytarabine 
Relapsed AML, high risk MDS Recruiting NCT02649764 - 
  I 
LY2606368 + cisplatin, 
cetuximab, pemetrexed, 
fluorouracil and/or 
leucovorin 
Solid tumors Recruiting NCT02124148 - 
 
LY2606368 + 
targeted therapy 
I 
LY2606368 + ralimetinib 
(MAPK inhibitor) 
Solid tumors Recruiting NCT02860780 - 
 LY2606368 + RT I 
LY2606368 + RT + 
cisplatin or cetuximab 
Locally advanced HNSCC Recruiting NCT02555644 - 
WEE1 AZD1775 II AZD1775 SCLC Recruiting NCT02593019 - 
  I AZD1775 Solid tumors 8% (2/25) PR: BRCAmut NCT01748825 (77,82) 
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ovarian, BRCAmut HNSCC 
  I AZD1775 Solid tumors Recruiting NCT02482311 (160) 
  I AZD1775 Solid tumors Recruiting NCT02610075 - 
 
AZD1775 + 
chemotherapy 
II 
Carboplatin / paclitaxel ± 
AZD1775 
Ovarian, TP53mut Complete, full results awaited NCT01357161 (85) 
  II Carboplatin + AZD1775 
Ovarian, TP53mut or platinum 
resistant 
ORR 9/21 (43%), with 
prolonged CR in 1/21 (5%).  
Median PFS: 5.3 months. 
Median OS: 12.6 months; two 
patients with ongoing 
response for more than 31 
and 42 months at data cutoff. 
NCT01164995 (84) 
  II Gemcitabine ± AZD1775 
Ovarian, Primary Peritoneal, or 
Fallopian 
Recruiting NCT02101775 - 
  II 
Carboplatin / pemetrexed 
± AZD1775 
NSCLC, 1st line Complete, full results awaited NCT02087241 - 
  II Docetaxel + AZD1775 NSCLC, 2nd line Closed NCT02087176 - 
  II 
Carboplatin / Paclitaxel + 
AZD1775 
NSCLC Recruiting NCT02513563 - 
  II 
Paclitaxel weekly + 
AZD1775  
Gastric carcinoma Recruiting NCT02448329 - 
  II Cisplatin ± AZD1775 HNSCC Complete, full results awaited NCT02196168 - 
  I / II Gemcitabine / nab- Pancreatic Recruiting NCT02194829 - 
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paclitaxel ± AZD1775 
  I / II Irinotecan + AZD1775 Pediatric solid tumors Recruiting NCT02095132 - 
  I 
Cisplatin / docetaxel + 
AZD1775 
Locally advanced HNSCC Recruiting NCT02508246 - 
  I 
Gemcitabine, cisplatin or 
carboplatin + AZD1775 
Solid tumors 
PR in 17/176 (10%). RR 
higher in TP53-mutated vs 
wild-type patients: 21% (n = 
19) vs 12% (n=33) 
NCT00648648 (83) 
 
AZD1775 + 
targeted therapy 
I 
AZD1775 + olaparib (PARP 
inhibitor) 
Solid tumors Complete, full results awaited NCT02511795 (161) 
   
AZD1775 + Belinostat 
(HDAC inhibitor) 
AML, other myeloid 
malignancies 
Recruiting NCT02381548 - 
 AZD1775 + RT I / II 
Radiation + gemcitabine + 
AZD1775 
Pancreatic Recruiting NCT02037230 - 
  I 
Radiation + cisplatin + 
AZD1775 
HNSCC Recruiting NCT02585973 (162) 
  I RT + cisplatin + AZD1775 
Locally advanced cervical 
cancer 
Recruiting NCT01958658 - 
  I 
Radiation + temozolomide 
+ AZD1775 
GBM Recruiting NCT01849146 - 
  I Radiation + AZD1775 Pediatric DIPG Recruiting NCT01922076 - 
 
AZD1775 + 
immune 
I MEDI4736 + AD1775 Solid tumors Recruiting NCT02617277 - 
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checkpoint 
inhibitor 
BER TRC102 I TRC102 Solid tumors, lymphoma Complete, full results awaited NCT01851369 (90) 
 
TRC102 + 
chemotherapy 
II TRC102 + temozolomide GBM Recruiting NCT02395692 - 
  I / II 
TRC102 + cisplatin and/or 
pemetrexed 
Solid tumors Recruiting NCT02535312 - 
  I TRC102 + pemetrexed Solid tumors 4% (1/28) PR: HNSCC NCT00692159 (89) 
  I TRC102 + fludarabine Haematologic malignancies Complete, full results awaited NCT01658319 - 
 TRC102 + RT I 
TRC + RT + cisplatin ± 
pemetrexed 
NSCLC Recruiting NCT02535325 - 
 
Table 2: Monotherapy and combination trials involving DDR inhibitors that have completed or are still active (www.clinicaltrials.gov). 
CLL, chronic lymphocytic leukemia; CR, complete response; CRUK, Cancer Research UK; DIPG, diffuse intrinsic pontine gliomas; ES, 
Ewing’s sarcoma; GBM, glioblastoma multiforme; GOJ, gastro-oesphageal carcinoma; HDAC, Histone deacetylase; HGSOC, high grade 
serous ovarian carcinoma; HNSCC, head and neck squamous cell carcinoma; mAb, monoclonal antibody; NCI, National Cancer Institute; 
NSCLC, non-small cell lung carcinoma; ORR, objective response rate; PLD, pegylated liposomal doxorubicin; PLL, prolymphocytic 
leukaemia; PR, partial response; RT, radiotherapy; SCLC, small cell lung carcinoma. 1 Dual DNA-PK and mTOR inhibitor. 
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FIGURE LEGENDS 
Figure 1  
Table showing predominant sensors, signaling and effector proteins for major 
DNA repair pathway. Main targets of drug development are in red (see text for 
details). 
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Figure 2  
DNA DSB repair signaling pathways through the apical DDR kinases. 
A. DNA-PK: Ku binds to DNA DSBs and recruits DNA-PKcs. Upon DNA 
binding, autophosphorylation of DNA-PKcs induces a conformational change 
that destabilises the NHEJ core complex, causing sliding of Ku inwards on the 
DNA and enabling access of end-processing and ligation enzymes to DNA 
ends and facilitation of repair. 
B. ATM: Following DSBs ATM is predominantly activated through interactions 
with NBS1 of the MRN complex. ATM is the principle kinase responsible for 
phosphorylation of histone H2AX on serine 139 (known as γH2AX). MDC1 
(mediator of DNA damage checkpoint protein1) directly binds γH2AX and 
potentiates DNA damage signaling leading to spreading of γH2AX to over a 
megabase from its initial lesion. This in turn promotes recruitment and 
retention of DNA damage mediator proteins such as 53BP1. CHK2 is a well-
studied ATM substrate. 
C. ATR: ATR is activated by RPA (replication protein A) bound to ssDNA. The 
ATR-CHEK1 signaling cascade activates the G2-M checkpoint, promotes 
replication fork stabilisation and slows DNA replication by suppressing origin 
firing.  
 
 
